
In part 2, Susan M. Wescott, RPh, MBA, discusses how payers navigate evidence gaps, prior authorization, and access to rare disease therapies.

Susan M. Wescott, RPh, MBA, is the senior director of managed care pharmacy at Mayo Clinic.

In part 2, Susan M. Wescott, RPh, MBA, discusses how payers navigate evidence gaps, prior authorization, and access to rare disease therapies.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.